Liquidia Technologies (LQDA) PT Raised to $41 at Wedbush, After Company Announces FDA Acceptance Of NDA For LIQ861 (Treprostinil) Inhalation Powder For The Treatment Of Pulmonary Arterial Hypertension
Tweet Send to a Friend
Wedbush analyst Liana Moussatos raised ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
